Anavex Life Sciences (AVXL) Total Current Liabilities (2012 - 2022)

Anavex Life Sciences (AVXL) has 11 years of Total Current Liabilities data on file, last reported at $9.5 million in Q2 2022.

• For the quarter ending Q2 2022, Total Current Liabilities changed N/A year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2022 stood at $9.5 million (changed N/A YoY), and the FY2021 full-year result was $10.8 million, up 47.81% from the prior year.
• Total Current Liabilities advanced to $9.5 million in Q2 2022, from $8.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.8 million in Q3 2021 to a low of $3.2 million in Q2 2018.
• A 5-year average of $6.6 million and a median of $6.4 million in 2019 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 120.62% in 2018 and decreased 2.23% in 2020, its largest moves.
• Tracing AVXL's Total Current Liabilities over 5 years: stood at $4.9 million in 2018, then climbed by 12.06% to $5.5 million in 2019, then soared by 47.03% to $8.0 million in 2020, then surged by 31.06% to $10.5 million in 2021, then retreated by 9.92% to $9.5 million in 2022.
• Business Quant data shows AVXL's Total Current Liabilities at $9.5 million in Q2 2022, $8.1 million in Q1 2022, and $10.5 million in Q4 2021.